Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 2
2004 3
2005 2
2006 7
2007 4
2008 5
2009 6
2010 9
2011 10
2012 10
2013 7
2014 15
2015 12
2016 15
2017 17
2018 13
2019 7
2020 6
2021 9
2022 15
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
[Molecular diagnosis of tuberculosis].
Morel F, Jaffré J, Sougakoff W, Aubry A, Véziris N. Morel F, et al. Among authors: veziris n. Rev Mal Respir. 2020 May;37(5):412-416. doi: 10.1016/j.rmr.2019.09.004. Epub 2020 Apr 22. Rev Mal Respir. 2020. PMID: 32334967 Free article. Review. French.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: veziris n. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Review.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilb… See abstract for full author list ➔ Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, et al. Among authors: veziris n. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Lancet. 2018. PMID: 30215381 Free PMC article. Review.
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Griffith DE, et al. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC. Am J Respir Crit Care Med. 2018. PMID: 30216086 Clinical Trial.
Multidrug and extensively drug-resistant tuberculosis.
Maitre T, Aubry A, Jarlier V, Robert J, Veziris N; CNR-MyRMA. Maitre T, et al. Among authors: veziris n. Med Mal Infect. 2017 Feb;47(1):3-10. doi: 10.1016/j.medmal.2016.07.006. Med Mal Infect. 2017. PMID: 27637852 Review.
[Managing multidrug-resistant tuberculosis].
Antoun F, Véziris N. Antoun F, et al. Among authors: veziris n. Rev Mal Respir. 2011 Oct;28(8):956-7. doi: 10.1016/j.rmr.2011.06.010. Epub 2011 Oct 12. Rev Mal Respir. 2011. PMID: 22099400 French. No abstract available.
Rifabutin: where do we stand in 2016?
Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. Crabol Y, et al. Among authors: veziris n. J Antimicrob Chemother. 2016 Jul;71(7):1759-71. doi: 10.1093/jac/dkw024. Epub 2016 Mar 23. J Antimicrob Chemother. 2016. PMID: 27009031 Review.
[Tuberculosis: New findings on an old infectious disease].
Aubry A, Veziris N. Aubry A, et al. Among authors: veziris n. Med Sci (Paris). 2023 Mar;39(3):203-204. doi: 10.1051/medsci/2023054. Epub 2023 Mar 21. Med Sci (Paris). 2023. PMID: 36943114 Free article. French. No abstract available.
168 results